NervGen Pharma Corp.
$4
▼
-2.29%
2026-04-21 08:24:00
www.nervgen.com
NCM: NGEN
Explore NervGen Pharma Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$464.51 M
Current Price
$4
52W High / Low
$8.49 / $2.57
Stock P/E
—
Book Value
$-0.03
Dividend Yield
—
ROCE
-721.31%
ROE
-14.58%
Face Value
—
EPS
$-0.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.99
Debt / Equity
0.24
Current Ratio
1.16
Quick Ratio
1.16
Forward P/E
-19.47
Price / Sales
—
Enterprise Value
$305.71 M
EV / EBITDA
-12.22
EV / Revenue
—
Rating
Buy
Target Price
$8.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 2. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 3. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 4. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
| 5. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 6. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
| 7. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.4 M | -6.17 M | -6.47 M | -6.04 M | -6.81 M | — |
| Net Profit | -26.91 M | -4.16 M | -9.1 M | -3.95 M | -8.61 M | — |
| EPS in Rs | -0.33 | -0.05 | -0.11 | -0.05 | -0.11 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -25.08 M | -25.18 M | -17.78 M | -23.03 M |
| Net Profit | -44.12 M | -24.25 M | -22.38 M | -20.72 M |
| EPS in Rs | -0.55 | -0.3 | -0.28 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 23.21 M | 19.49 M | 13.24 M | 23.88 M |
| Total Liabilities | 19.73 M | 16.91 M | 15.25 M | 10.41 M |
| Equity | 3.48 M | 2.58 M | -2.01 M | 13.46 M |
| Current Assets | 22.8 M | 19.01 M | 12.52 M | 23.15 M |
| Current Liabilities | 19.73 M | 16.9 M | 15.14 M | 10.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.5 M | -16.84 M | -11.3 M | -17.78 M |
| Investing CF | 0.1 M | 0.06 M | -0.14 M | -0.02 M |
| Financing CF | 23.76 M | 22.7 M | 0.77 M | 22.64 M |
| Free CF | -19.5 M | -16.84 M | -11.44 M | -17.81 M |
| Capex | — | — | -0.14 M | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -8.35% | -8.01% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.